C=x Bonded Directly To The Five-membered Hetero Ring By Nonionic Bonding (x Is Chalcogen) Patents (Class 514/423)
  • Patent number: 10966968
    Abstract: In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of reducing triglycerides in a subject on rosiglitazone therapy, the method comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof.
    Type: Grant
    Filed: June 6, 2014
    Date of Patent: April 6, 2021
    Assignee: Amarin Pharmaceuticals Ireland Limited
    Inventors: Rene Braeckman, William Stirtan, Paresh Soni
  • Patent number: 10874624
    Abstract: Provided are pharmaceutical dosage forms comprising (i) trientine or a pharmaceutically acceptable salt of trientine, in a (ii) sealed packaging. The sealed packaging provides a high barrier protection against air, moisture and light and prevents exposure of the drug to conditions that facilitate its decomposition. The pharmaceutical dosage forms are useful for treating diseases or conditions where excess copper is not removed from the body, e.g., Wilson's disease.
    Type: Grant
    Filed: February 3, 2016
    Date of Patent: December 29, 2020
    Assignee: KADMON PHARMACEUTICALS, LLC
    Inventor: Samuel D. Waksal
  • Patent number: 10857116
    Abstract: Amino acids compositions for use in the treatment of pain in patients who underwent elective arthroplasty.
    Type: Grant
    Filed: September 8, 2016
    Date of Patent: December 8, 2020
    Assignee: Professional Dietetics International S.r.l.
    Inventor: Paolo Luca Maria Giorgetti
  • Patent number: 10821078
    Abstract: The present invention provides nanomaterials for the specific targeting of immune cells. Methods of treating cardiac disease and inflammatory disease are also described.
    Type: Grant
    Filed: June 29, 2017
    Date of Patent: November 3, 2020
    Assignee: Northwestern University
    Inventors: Evan A. Scott, Sijia Yi, Sean D. Allen
  • Patent number: 10786690
    Abstract: The present invention thus relates to amide derivatives of polysubstituted quinic acids (abbreviated to “QPS”), of general formula (IA): (IA), in which —R1A and R2A are, independently of one another: H, with the proviso that R1A and R2A are not both a hydrogen atom, a butyl group, a C7-C30 alkyl group, —a C7-C30 alkylaryl or arylalkyl group, or a C7-C18 aryl group; and —Q1, Q3, Q4 and Q5 are, independently of one another, an OH, caffeoyl, maloyl, caffeoylmaloyl ou maloylcaffeoyl group, with the proviso that at least one of these radicals is not an OH group, or to a pharmaceutically acceptable salt or stereoisomer or hydrate thereof, and also to the process for producing same, to the use thereof as a medicament, in particular for the treatment and/or prevention of inflammation and of inflammatory diseases, and to the pharmaceutical, cosmetic and nutraceutical compositions containing same.
    Type: Grant
    Filed: April 26, 2017
    Date of Patent: September 29, 2020
    Assignee: TEMISIS
    Inventors: Damien Boeglin, Pierre Warnault
  • Patent number: 10736871
    Abstract: The present invention relates to, in part, methods for the treatment of methanogen-associated disorders such as, for example, Irritable Bowel Syndrome (IBS) using at least one anti-methanogenic lovastatin analog or derivative. In addition, modified-release formulations comprising at least one anti-methanogenic lovastatin analog or derivative are provided which release the anti-methanogenic lovastatin analog or derivative in the gastrointestinal tract.
    Type: Grant
    Filed: March 31, 2016
    Date of Patent: August 11, 2020
    Assignees: Cedars-Sinai Medical Center, Synthetic Biologics, Inc.
    Inventors: Mark Pimentel, Vince Wacher
  • Patent number: 10722533
    Abstract: Provided are nutritional supplements designed for enhancing the growth, particularly the linear growth, of pre-pubertal children with a stature measure short compared to the norm. The nutritional composition includes an energy source, arginine and a combination of micronutrients.
    Type: Grant
    Filed: January 22, 2018
    Date of Patent: July 28, 2020
    Assignee: NG Solutions LTD
    Inventors: Moshe Phillip, Michal Yackobovitch-Gavan, Raanan Shamir, Hadassa Bymel, Liora Lazar
  • Patent number: 10716752
    Abstract: Certain embodiments involve gastric residence structures which can be administered to a subject (e.g., a patient) in a configuration constrained by a retaining element, and configured to mediate a change in shape when unconstrained by the retaining element to assume a configuration in the stomach in which is retained and unable to pass through the gastric pyloric orifice of the subject under gastrointestinal physiological conditions. The residence structures can be loaded with an agent for release in the stomach.
    Type: Grant
    Filed: November 22, 2019
    Date of Patent: July 21, 2020
    Assignees: Massachusetts Institute of Technology, The Brigham and Women's Hospital, Inc.
    Inventors: Andrew Bellinger, Shiyi Zhang, Carlo Giovanni Traverso, Robert S. Langer, Stacy Mo, Tyler Grant, Mousa Jafari, Dean Liang Glettig, Angela DiCiccio, Lowell L. Wood, Jr., Philip A. Eckhoff
  • Patent number: 10716751
    Abstract: Certain embodiments involve administering a residence structure to a subject (e.g., a patient) in a constrained configuration, then unconstraining the structure such that it is retained at a location internally of the subject for a period of time. The structure includes a loadable component that can carry an active substance for release internally of the subject.
    Type: Grant
    Filed: November 22, 2019
    Date of Patent: July 21, 2020
    Assignees: Massachusetts Institute of Technology, The Brigham and Women's Hospital, Inc.
    Inventors: Andrew Bellinger, Shiyi Zhang, Carlo Giovanni Traverso, Robert S. Langer, Stacy Mo, Tyler Grant, Mousa Jafari, Dean Liang Glettig, Angela DiCiccio, Lowell L. Wood, Jr., Philip A. Eckhoff
  • Patent number: 10689339
    Abstract: The invention relates to a compound of formula (I) wherein R1 and R2 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Grant
    Filed: August 24, 2018
    Date of Patent: June 23, 2020
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Wolfgang Haap, Bernd Kuhn, Thomas Luebbers, Jens-Uwe Peters
  • Patent number: 10688155
    Abstract: The present invention is directed to a method of treating a metabolic disorder or key elements of a metabolic disorder such method comprising the use of an agent(s) that increases central dopaminergic activity plus a first-phase insulin secretagouge.
    Type: Grant
    Filed: January 18, 2018
    Date of Patent: June 23, 2020
    Assignee: VeroScience LLC
    Inventor: Anthony H. Cincotta
  • Patent number: 10682329
    Abstract: Obesity is inhibited by administering to a person in need thereof an effective amount of entacapone ((2E)-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethylprop-2-enamide), or a pharmaceutically-acceptable salt thereof, particularly in conjunction with a second, different anti-obesity medicament. Pharmaceutical compositions comprise entacapone copackaged or coformulated with a second, different anti-obesity medicament.
    Type: Grant
    Filed: June 26, 2018
    Date of Patent: June 16, 2020
    Assignee: National Institute of Biological Sciences, Beijing
    Inventors: Niu Huang, Gang Zhi, Jijie Chai, Shiming Peng, Nannan Hou
  • Patent number: 10513494
    Abstract: Methods of treatment useful in the inducement or maintenance of anesthesia in a subject are provided. The methods comprise administering to a subject in need of anesthesia a compound disclosed herein. Also provided are novel compounds having anesthetic effects, pharmaceutical compositions comprising the compounds, and packaged pharmaceuticals. Computer modeling of the compounds demonstrates favorable interactions with the GABA receptor type A. In addition, the compounds display reversible anesthetic effects in an animal model, with dose-response curves similar to those of known general anesthetics. GABA receptor-mediated effects are also demonstrated in a hippocampal brain slice preparation.
    Type: Grant
    Filed: December 5, 2018
    Date of Patent: December 24, 2019
    Assignees: The Board of Trustees of the Leland Stanford Junior University, The United States Government as represented by the Department Of Veterans Affairs
    Inventors: Edward John Bertaccini, Margaret Frances Davies
  • Patent number: 10500187
    Abstract: Plant phenols, in particular, plant phenolic acids, like rosmarinic acid, ellagic acid, and chlorogenic acid, are used in preventing or reducing transepidermal water loss (TEWL) and associated disorders and diseases.
    Type: Grant
    Filed: September 12, 2013
    Date of Patent: December 10, 2019
    Assignee: Societe des Produits Nestle S.A.
    Inventors: Carine Blanchard, Marjorie Guitard, Sebastien Holvoet
  • Patent number: 10493059
    Abstract: The present invention is directed to the treatment of paroxysmal extreme pain disorder (PEPD) comprising administering to a subject in need thereof, a therapeutically effective amount of 5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-prolinamide or a pharmaceutically acceptable salt, solvate or prodrug thereof.
    Type: Grant
    Filed: October 2, 2015
    Date of Patent: December 3, 2019
    Assignee: Convergence Pharmaceuticals Limited
    Inventor: Valerie Morisset
  • Patent number: 10441568
    Abstract: Cyclic nitroxide compounds including, but not limited to, compounds having the general formula I: wherein the dashed line and R1-R8 are as defined herein, are disclosed herein for use in treating diseases and disorders of the respiratory tract and/or respiratory tract remodeling.
    Type: Grant
    Filed: March 24, 2016
    Date of Patent: October 15, 2019
    Assignees: Yissum Research Development Company of the Hebrew University of Jerusalem Ltd., Hadasit Medical Research Services and Development Ltd.
    Inventors: Sara Goldstein, Amram Samuni, Neville Berkman
  • Patent number: 10414750
    Abstract: The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of lysine specific demethylase-1. Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as prostate cancer, breast cancer, bladder cancer, lung cancer and/or melanoma and the like.
    Type: Grant
    Filed: June 30, 2015
    Date of Patent: September 17, 2019
    Assignee: Celgene Quanticel Research, Inc.
    Inventors: Young K. Chen, Toufike Kanouni, Zhe Nie, Jeffrey Alan Stafford, James Marvin Veal
  • Patent number: 10357470
    Abstract: Compositions comprising chelating agents, metal ion salts, gelling agents or a buffer, antimicrobials, antibiofilm agents and a pH adjuster or a buffer for the prevention and treatment of wound infections and food-borne diseases involving bacterial biofilms are disclosed. The anti-infective properties of a composition include reduction or killing of anaerobic/aerobic/facultative gram-negative and gram-positive wound infection associated bacteria occurring in polymicrobial biofilms. The composition may be in the form of lotion, cream, ointment, dressing, bandage, rinse, soak, gel, spray, or other suitable forms, including certain devices. Additionally, the invention offers an efficient method of delivering the formulated composition containing one or two chelating agents or chelating agents alone or in combination with a metal ion salt using either a nanoparticle or other efficient delivery systems.
    Type: Grant
    Filed: July 18, 2017
    Date of Patent: July 23, 2019
    Assignee: KANE BIOTECH INC.
    Inventors: Purushottam V. Gawande, Karen Lovetri, Nandadeva Yakandawala, Gordon Froehlich, Srinivasa Madhyastha
  • Patent number: 10329252
    Abstract: The present invention provides a compound represented by General Formula (I). The compound according to the present invention prevents the liquid crystal composition from being deteriorated due to light, has high compatibility with the liquid crystal composition, and does not impair the storage stability of the liquid crystal composition, thus the compound is useful as a constituent member of a liquid crystal composition. Since the liquid crystal composition and the liquid crystal display element containing the compound of the present invention exhibit UV resistance and have a high VHR, it is possible to obtain a liquid crystal display element with excellent display quality in which display defects such as burn-in and display unevenness do not occur or are suppressed.
    Type: Grant
    Filed: August 23, 2016
    Date of Patent: June 25, 2019
    Assignee: DIC CORPORATION
    Inventors: Yoshio Aoki, Ayaki Hosono
  • Patent number: 10314803
    Abstract: The present invention relates to, inter alia, pharmaceutical compositions comprising eicosapentaenoic acid and/or derivatives thereof and nicotinic acid, to methods of manufacturing such compositions, and to therapeutic methods for treating carious diseases and disorders.
    Type: Grant
    Filed: December 5, 2012
    Date of Patent: June 11, 2019
    Assignee: Amarin Pharmaceuticals Ireland Limited
    Inventor: Mehar Manku
  • Patent number: 10308597
    Abstract: This invention relates to compounds that inhibit creatine transport and/or creatine kinase, pharmaceutical compositions including such compounds, and methods of utilizing such compounds and compositions for the treatment of cancer.
    Type: Grant
    Filed: April 30, 2015
    Date of Patent: June 4, 2019
    Assignee: Rgenix, Inc.
    Inventors: Eduardo J. Martinez, Sohail F. Tavazoie
  • Patent number: 10159648
    Abstract: This invention relates to novel extended release pharmaceutical compositions of levetiracetam and preparations and characterizations thereof. This invention further relates to using these extended release pharmaceutical compositions of levetiracetam for the treatment of cognitive impairment associated with central nervous system (CNS) disorders in a subject in need or at risk thereof.
    Type: Grant
    Filed: May 20, 2016
    Date of Patent: December 25, 2018
    Assignee: AgeneBio, Inc.
    Inventors: Michela Gallagher, Sharon Rosenzweig-Lipson, Elsie Melsopp, Jack Lawrence James
  • Patent number: 10113171
    Abstract: An active agent capable of reducing quinone reductase 2 activity, for use in improvement of cognition in a subject is provided. Such an active agent may be a nucleic acid molecule that reduces the gene expression level of quinone reductase 2 or an inhibitor of quinone reductase 2 activity. A vector comprising a nucleic acid molecule that reduces the gene expression level of quinone reductase 2 and a pharmaceutical composition comprising an active agent capable of reducing quinone reductase 2 activity or said vector are provided as well.
    Type: Grant
    Filed: March 18, 2015
    Date of Patent: October 30, 2018
    Assignee: Carmel-Haifa University Economic Corp. Ltd.
    Inventors: Kobi Rosenblum, Akiva Rappaport
  • Patent number: 10100010
    Abstract: The present invention provides a 4-methoxy pyrrole derivative or a pharmaceutically acceptable salt thereof, a preparation method thereof, and a pharmaceutical composition containing the same. The 4-methoxy pyrrole derivatives or pharmaceutically acceptable salts thereof according to the present invention have not only excellent proton pump inhibitory activity, gastric damage-inhibiting activity and defensive factor-enhancing effects, but also excellent eradication activity against H. pylori. Therefore, the 4-methoxy pyrrole derivatives or pharmaceutically acceptable salts thereof can be effectively used for the prevention and treatment of gastrointestinal damage due to gastrointestinal tract ulcer, gastritis, reflux esophagitis or H. pylori.
    Type: Grant
    Filed: April 27, 2016
    Date of Patent: October 16, 2018
    Assignee: Daewoong Pharmaceutical Co., Ltd.
    Inventors: Chun Ho Lee, Seung Chul Lee, Yeon Im Lee, Deok Ki Eom, Mi Ryeong Han, Eun Ji Koh
  • Patent number: 10100003
    Abstract: Disclosed are salts, such as nitrates, of acetyl-L-carnitine and propionyl-L-carnitine and methods of making the compounds.
    Type: Grant
    Filed: February 21, 2017
    Date of Patent: October 16, 2018
    Assignee: Thermolife International, LLC
    Inventors: Ronald Kramer, Alexander Nikolaidis
  • Patent number: 10071962
    Abstract: Compounds having a structure of Structure I: or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R1, R2, R3, R4, R6, Y1 and Y2 are as defined herein, and wherein at least one of R3 or R4 is a straight-chain C1-C6 haloalkyl, are provided. Uses of such compounds for treatment of various indications, including prostate cancer, as well as methods of treatment involving such compounds are also provided.
    Type: Grant
    Filed: June 19, 2017
    Date of Patent: September 11, 2018
    Assignees: British Columbia Cancer Agency Branch, The University of British Columbia
    Inventors: Luping Yan, Raymond J. Andersen, Marianne Dorothy Sadar, Nasrin R. Mawji, Carmen Adriana Banuelos
  • Patent number: 10052281
    Abstract: A dysphagia improving composition characterized in that a substance having an inhibitory action on an angiotensin converting enzyme, which is a degrading enzyme of substance P, is administered locally in a dosage not influencing blood pressure, and a pharmaceutical for improving dysphagia containing the composition.
    Type: Grant
    Filed: May 8, 2017
    Date of Patent: August 21, 2018
    Assignee: Meiji Seika Pharma Co., Ltd.
    Inventors: Koichi Kitamura, Maho Kondo, Kiyoshi Shimoyama, Toru Kurosawa
  • Patent number: 10016393
    Abstract: The present disclosure relates to: (a) methods of using stabilized pharmaceutical dosage forms comprising atrasentan, or a pharmaceutically acceptable salt thereof, and, optionally, another therapeutic agent to treat type 2 diabetes, microalbuminuria or macroalbuminuria; and (b) methods for the preparation of such pharmaceutical dosage forms.
    Type: Grant
    Filed: May 13, 2016
    Date of Patent: July 10, 2018
    Assignee: AbbVie Inc.
    Inventors: Ye Huang, Andrew K. Koski, Katherine E. Peterson
  • Patent number: 10015980
    Abstract: A method includes a step of identifying a subject in need of diet modification; and administering a first diet to the subject for a first time period. The first diet provides 4.5 to 7 kilocalories per pound of subject for a first day and 3 to 5 kilocalories per pound of subject per day for a second to fifth day of the first diet. The first diet includes less than 30 g of sugar on the first day; less than 20 g of sugar on the second to fifth days; less than 28 g of proteins on the first day; less than 18 g of proteins on days the second to fifth days; 20 to 30 grams of monounsaturated fats on the first day; 10 to 15 grams of monounsaturated fats on the second to fifth days; and between 6 and 10 grams of polyunsaturated fats on the first day.
    Type: Grant
    Filed: October 22, 2013
    Date of Patent: July 10, 2018
    Assignee: UNIVERSITY OF SOUTHERN CALIFORNIA
    Inventors: Valter D. Longo, Chia-Wei Cheng, Sebastian Brandhorst, Min Wei
  • Patent number: 9938238
    Abstract: Provided herein are methods and compositions for controlling auxin responses in plants.
    Type: Grant
    Filed: September 13, 2016
    Date of Patent: April 10, 2018
    Assignee: The Regents of the University of California
    Inventor: Paul Brian Larsen
  • Patent number: 9839668
    Abstract: The present invention relates to a pharmaceutical composition comprising a. at least one aspartyl aminopeptidase inhibitor and at least one angiotensin-converting-enzyme (ACE) inhibitor, or b. at least one aspartyl aminopeptidase inhibitor and at least one chymase inhibitor. In an embodiment, the pharmaceutical composition comprises at least one aspartyl aminopeptidase inhibitor and at least one angiotensin-converting-enzyme (ACE) inhibitor and at least one chymase inhibitor. Furthermore, the invention relates to a pharmaceutical composition possessing inhibitory activity against a. aspartyl aminopeptidase and angiotensin-converting-enzyme (ACE), or b. against aspartyl aminopeptidase and chymase. In a third aspect, the invention relates to a kit of parts comprising a. a pharmaceutical composition comprising an aspartyl aminopeptidase inhibitor and a pharmaceutical composition comprising an angiotensin-converting-enzyme (ACE) inhibitor, or b.
    Type: Grant
    Filed: December 11, 2014
    Date of Patent: December 12, 2017
    Assignee: ATTOQUANT DIAGNOSTICS GMBH
    Inventors: Marko Poglitsch, Cornelia Schwager, Hans Loibner
  • Patent number: 9820966
    Abstract: The present invention is directed to statin formulations having improved solubility and/or stability and methods for the same.
    Type: Grant
    Filed: November 11, 2014
    Date of Patent: November 21, 2017
    Assignee: CUMBERLAND PHARMACEUTICALS
    Inventors: Leo Pavliv, Andrew Vila
  • Patent number: 9782336
    Abstract: The present invention provides a composition containing (A) and (B), which shows a decreased peculiar odor of acylproline and a salt thereof, has a moist feeling and is superior in the stability: (A) acylproline represented by the formula (1) or a salt thereof (wherein an acyl group represented by R1—CO— is an acyl group induced from saturated or unsaturated fatty acid having 3-23 carbon atoms) (B) a zinc salt of pyrrolidone carboxylate.
    Type: Grant
    Filed: March 10, 2017
    Date of Patent: October 10, 2017
    Assignee: AJINOMOTO CO., INC.
    Inventors: Nana Haraya, Eiko Oshimura
  • Patent number: 9682933
    Abstract: Compounds having a structure of Structure I: or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R1, R2, R3, R4, R6, Y1 and Y2 are as defined herein, and wherein at least one of R3 or R4 is a straight-chain C1-C6 haloalkyl, are provided. Uses of such compounds for treatment of various indications, including prostate cancer, as well as methods of treatment involving such compounds are also provided.
    Type: Grant
    Filed: May 29, 2015
    Date of Patent: June 20, 2017
    Assignees: British Columbia Cancer Agency Branch, The University of British Columbia
    Inventors: Luping Yan, Raymond J. Andersen, Marianne Dorothy Sadar, Nasrin R. Mawji, Carmen Adriana Banuelos
  • Patent number: 9676713
    Abstract: The present invention provides a production intermediate of an atropisomer of a pyrrole derivative having excellent mineralocorticoid receptor antagonistic activity, a method for producing the same, and a crystal thereof. A method for producing an atropisomer of a pyrrole derivative including a step of resolving a compound represented by the following general formula (I) [wherein R1 represents a methyl group or a trifluoromethyl group, R2 represents a hydrogen atom or a C1-C3 alkoxy group, and n represents an integer selected from 1 to 3] into its atropisomers, characterized by using an optically active amine having a cinchonine skeletal formula, and a crystal of (S)-1-(2-hydroxyethyl)-4-methyl-N-[4-(methylsulfonyl)phenyl]-5-[2-(trifluoromethyl)phenyl]-1H-pyrrole-3-carboxamide.
    Type: Grant
    Filed: November 15, 2016
    Date of Patent: June 13, 2017
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Masashi Watanabe, Takahiro Okachi, Michiaki Kawahara, Hiroshi Nagasawa, Noritada Sato, Takashi Takita, Gen Hasegawa
  • Patent number: 9616046
    Abstract: The present invention relates to a hepatocyte-proliferating agent comprising pyroglutamic acid, aspartic acid, and glutamic acid as active ingredients, in particular, a hepatocyte-proliferating agent capable of selectively proliferating normal hepatocytes without proliferating cancer cells.
    Type: Grant
    Filed: June 16, 2014
    Date of Patent: April 11, 2017
    Assignee: JAPAN BIO PRODUCTS Co., Ltd.
    Inventors: Shinjiro Inoue, Eiichi Hirano, Tetsuo Morinaga
  • Patent number: 9612242
    Abstract: Diagnostic tests for characterizing an individual's risk of developing or having a cardiovascular disease. In one embodiment the present diagnostic test comprises determining the level of myeloperoxidase (MPO) activity in a bodily sample obtained from the individual or test subject. In another embodiment, the diagnostic test comprises determining the level of MPO mass in a bodily sample obtained from the test subject. In another embodiment, the diagnostic test comprises determining the level of one or more select MPO-generated oxidation products in a bodily sample obtained from the test subject. The select MPO-generated oxidation products are dityrosine, nitrotyrosine, methionine sulphoxide or an MPO-generated lipid peroxidation products.
    Type: Grant
    Filed: January 7, 2015
    Date of Patent: April 4, 2017
    Assignee: The Cleveland Clinic Foundation
    Inventors: Stanley L. Hazen, Renliang Zhang
  • Patent number: 9573883
    Abstract: Disclosed are salts, such as nitrates, of acetyl-L-carnitine and propionyl-L-carnitine and methods of making the compounds.
    Type: Grant
    Filed: December 15, 2014
    Date of Patent: February 21, 2017
    Assignee: ThermoLife International, LLC
    Inventors: Ronald Kramer, Alexander Nikolaidis
  • Patent number: 9522931
    Abstract: The present invention is directed to a novel process for the preparation of compounds having inhibitory activity against sodium-dependent glucose transporter (SGLT) being present in the intestine or kidney.
    Type: Grant
    Filed: May 18, 2012
    Date of Patent: December 20, 2016
    Assignee: Janssen Pharmaceutica NV
    Inventors: Kenneth M. Wells, Ronald K. Russell, Xun Li, Shawn Branum, Derek A. Beauchamp, Sumihiro Nomura, Yosuke Matsumura
  • Patent number: 9487505
    Abstract: The present invention relates to novel 1,3-dihydroindol-2-one (oxindole) derivatives of the formula (I) in which A, R3, R4, R5, R6 and R7 are defined according to claim 1, and to medicaments containing them for the treatment of diseases. In particular, the novel oxindole derivatives can be used for the control and/or prophylaxis of various vasopressin-dependent or oxytocin-dependent diseases.
    Type: Grant
    Filed: September 25, 2013
    Date of Patent: November 8, 2016
    Assignees: ABBVIE DEUTSCHLAND GMBH & CO. KG
    Inventors: Wilfried Lubisch, Wilfried Hornberger, Thorsten K. Oost, Daryl Richard Sauer, Liliane Unger, Wolfgang Wernet, Hervé Geneste
  • Patent number: 9422335
    Abstract: The present invention provides modified TLR2 ligands useful for modulating inflammatory responses. In particular, the ligands comprise (a) a fatty acid di- or tri-linoleate and (b) a GM1-binding peptide. The linoleate provides the anti-inflammatory function, while the GM1-binding peptide facilitates endocytosis.
    Type: Grant
    Filed: August 30, 2012
    Date of Patent: August 23, 2016
    Assignee: UTI Limited Partnership
    Inventors: Elizabeth M. Long, Stephen M. Robbins, Paul Kubes, Ela Kolaczkowska
  • Patent number: 9387234
    Abstract: A method is provided for increasing trafficking of endothelial progenitor cells to an ischemic myocardium in a subject's heart comprising administering to the subject's heart an amount of Stromal-Derived Factor-1 (SDF-1).
    Type: Grant
    Filed: July 10, 2013
    Date of Patent: July 12, 2016
    Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
    Inventor: Silviu Itescu
  • Patent number: 9346814
    Abstract: The present invention relates to novel inhibitors having high selectivity and specificity for FAP (fibroblast activation protein). Said inhibitors are useful as a human and/or veterinary medicine, in particular for the treatment and/or prevention of FAP-related disorders such as but not limited to proliferative disorders.
    Type: Grant
    Filed: January 17, 2013
    Date of Patent: May 24, 2016
    Assignees: Universiteit Antwerp, Fox Chase Cancer Center
    Inventors: Koen Jansen, Ingrid De Meester, Leen Heirbaut, Jonathan D Cheng, Jurgen Joossens, Koen Augustyns, Pieter Van Der Veken
  • Patent number: 9340500
    Abstract: A compound having TRPV4 inhibitory activity or a pharmaceutically acceptable salt thereof is provided. The present invention is related to a compound represented by the formula (I), wherein R1a is substituted or unsubstituted alkyl or the like; R1b is hydrogen or substituted or unsubstituted alkyl; R1c is hydrogen, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted nonaromatic heterocyclic group or the like; -L- is —C(=0)—NR2? or the like; X is substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl or the like, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: April 18, 2012
    Date of Patent: May 17, 2016
    Assignee: SHIONOGI & CO., LTD.
    Inventor: Akira Yukimasa
  • Patent number: 9226965
    Abstract: A method and composition for treating, preventing or ameliorating heart failure, cardiac hypertrophy, and/or myocardial dysfunction includes administering a therapeutically effective amount of a HDAC inhibitor, such as phenylbutyrate, in combination with an ACE inhibitor, such as captopril.
    Type: Grant
    Filed: October 3, 2008
    Date of Patent: January 5, 2016
    Assignee: U.S. DEPARTMENT OF VETERANS AFFAIRS
    Inventors: Wesley W. Brooks, Oscar H.L. Bing
  • Patent number: 9198942
    Abstract: A bioactive compound obtained from A. cinnamomea mycelium is prepared. The A. cinnamomea mycelium is solid-state cultivated. The bioactive compound is 2,3,6-trimethoxy-4-methylphenol and is called Leader 1. Leader 1 effectively suppresses movement, migration and invasion of lung cancer cells. Leader 1 achieves the effect of anti-metastasis and shows excellent resistance to physiological activity and mechanism on cancer metastasis.
    Type: Grant
    Filed: August 18, 2014
    Date of Patent: December 1, 2015
    Assignee: TAIWAN LEADER BIOTECH CORP.
    Inventors: Chin-Chung Lin, Jong-Tar Kuo, Ching-Chun Chen, Jent-turn Lee, Yu-Yen Lin
  • Patent number: 9198896
    Abstract: A pharmaceutical composition and treatment method to reduce the proliferation of cancerous or tumor cells, in which the combined active agents are methylglyoxal, ascorbic acid, creatine and melatonin.
    Type: Grant
    Filed: August 18, 2010
    Date of Patent: December 1, 2015
    Assignee: NATIONAL RESEARCH DEVELOPMENT CORPORATION
    Inventor: Manju Ray
  • Patent number: 9067884
    Abstract: The present invention relates to substituted pyrrole compounds and compositions comprising substituted pyrrole compounds. The invention further relates to methods of inhibiting the activity of Hsp90 in a subject in need thereof and methods for treating hyperproliferative disorders, such as cancer, in a subject in need thereof comprising administering to the subject a substituted pyrrole compound of the invention, or a pharmaceutical composition comprising such a compound.
    Type: Grant
    Filed: July 2, 2014
    Date of Patent: June 30, 2015
    Assignee: Synta Pharmaceuticals Corp.
    Inventors: Dinesh U. Chimmanamada, Weiwen Ying
  • Publication number: 20150147396
    Abstract: Nanoparticles are provided that comprise S-nitrosothiol (SNO) groups covalently bonded to the nanoparticles and/or S-nitrosothiol containing molecules encapsulated within the nanoparticles, as well as methods of making and using the nanoparticles. The invention also provides methods of preparing nanoparticles comprising Snitrosothiol (SNO) groups covalently bonded to the nanoparticles, where the methods comprise a) providing a buffer solution comprising chitosan, polyethylene glycol, nitrite, glucose, and hydrolyzed 3-mercaptopropyltrimethoxysilane (MPTS); b) adding hydrolyzed tetramethoxysilane (TMOS) to the buffer solution to produce a sol-gel; and c) lyophilizing and ball milling the sol-gel to produce nanoparticles of a desired size.
    Type: Application
    Filed: May 1, 2013
    Publication date: May 28, 2015
    Inventors: Parimala Nacharaju, Chaim Tuckman-Vernon, Adam J. Friedman, Pedro Cabrales, Joel M. Friedman
  • Publication number: 20150148360
    Abstract: The present invention provides novel compounds of Formula (I), and pharmaceutically compositions thereof. Compounds of Formula (I) are inhibitors of histone deacetylases (HDACs) and 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase (HMGR). Also provided are methods of using the compounds and pharmaceutical compositions for inhibiting the activity of HDACs and HMGR, treating diseases associated with HDACs or HMGR (e.g., cancer, hypercholesterolemia, an acute or chronic inflammatory disease, autoimmune disease, allergic disease, pathogen infection, neurodegenerative disease, and a disease associated with oxidative stress), or inhibiting drug resistance of cancer cells.
    Type: Application
    Filed: July 19, 2013
    Publication date: May 28, 2015
    Inventors: Jung-Hsin Lin, Jim-Min Fang, Ting-Rong Chen, Jhih-Bin Chen, Ching-Chow Chen, Tzu-Tang Wei